Wegovy® semaglutide tablets 25 mg, semaglutide injection 1.7mg, 2.4 mg, 7.2 mg logo

Prescribing Wegovy® through the Medicare GLP-1 Bridge Program

Medicare GLP-1 Bridge is a government program allowing eligible Medicare Part D patients to pay $50 per month for weight loss medications, like Wegovy®.a The program covers all doses of Wegovy® injections and tablets, with no deductible required. Wegovy® must be prescribed for adults for weight loss only.

aTerms apply. For eligible Medicare patients prescribed Wegovy® for weight loss only. Eligibility criteria will be determined by the Centers for Medicare and Medicaid Services (CMS). This information is not a guarantee of coverage. Month defined as 1 box of 4 pens of Wegovy® and 1 bottle of 30 tablets of Wegovy®. Visit wegovybridge.novomedlink.com to learn more. 

In addition to diet and exercise, Wegovy® (semaglutide) is indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Click for Limitations of Use.

Overview

What is Medicare Bridge?

The Medicare GLP-1 Bridge program is a short-term demonstration run by the Centers for Medicare and Medicaid Services.

Cost

$50 per month

No deductible

Use outside of Part D prescription coverage

Who’s it for?

Adults 18+ with Medicare Part D

Must be using Wegovy® for weight loss only and meet certain clinical criteria

What’s covered

Wegovy® pill and Wegovy® pen

All doses (strengths) are covered

Eligibility

Patient eligibility at a glance

Qualifying criteria

Age

Be 18 years or older

Lifestyle modifications

Participate in clinically appropriate lifestyle modifications consistent with the FDA-approved label for their prescribed medication

Indication

Be prescribed Wegovy® for weight loss or weight management

Disqualifying criteria

Patients are disqualified from Medicare GLP-1 Bridge if they do not meet the clinical criteria or if they can receive Wegovy® through standard Medicare Part D benefits. Patients with Type 2 diabetes or moderate to severe obstructive sleep apnea indications are eligible for Part D coverage and ineligible for the Medicare GLP-1 Bridge program.

Eligible BMI categories

Starting BMI

≥27

and 1+ of the following:

Pre-diabetes (defined by ADA guidelines)

Previous MI

Previous stroke

Symptomatic PAD

Starting BMI

≥30

and 1+ of the following:

HFpEF

Uncontrolled HTNb

CKD stage 3a or above

Starting BMI

≥35

No additional conditions required.

bUncontrolled hypertension (defined as systolic blood pressure above 140 mm Hg or diastolic blood pressure above 90 mm Hg, despite concurrent treatment with two antihypertensive medications).

Prescribing steps

How to prescribe Wegovy® for local pharmacy pick-up, step by step

Do not proactively submit a PA:
Start by sending the prescription to the pharmacy, which will then provide the correct prior authorization form to you. You can fill out the PA form either electronically or by fax.

1. Confirm eligibility

Confirm your patient is aged 18 or older and meets clinical criteria for Medicare GLP-1 Bridge.


2. Send the prescription with the additional information

Send the prescription to the pharmacy. Include “SEND TO BRIDGE FOR WEIGHT MANAGEMENT” in the note field if electronic, or as an annotation if non-electronic, so that the prescription is sent to the Medicare GLP-1 Bridge program and not the patient’s Part D plan.

Additional information that should be included with the script:

An obesity diagnosis code (the E66 family).

The patient's Medicare number, which can be found on their Medicare card.


3. Complete the PA when requested

The pharmacy will send an Electronic Prior Authorization (ePA) request or fax form to you for completion, typically within 24–72 hours.

If you haven’t received the ePA or fax form from the pharmacy, visit cms.gov/glp-1-bridge.pdf to get the fax form.

PA approval or denial will be mailed to your patient and faxed to you within 72 hours of submission, but most prior authorizations will be processed instantly.

If you believe a denial was made in error, you may resubmit the PA for re-review.

Pharmacy info

Pharmacist instructions

Use the information below, along with the patient's Medicare or Social Security number.

BIN

028918

PCN

MEDDGLP1BR

Group ID

GLP1Bridge

NDC numbers

No separate prescription is needed for needles as they are integrated into the Wegovy® pen device. Medicare GLP-1 Bridge patients do not need a new prior authorization if switching between Wegovy® pen and pill.

Resources

Novocare® HCP
support line

1-866-898-9368, Monday‑Friday, 8:00 am‑9:00 pm ET, Saturday, 9:00 am‑5:00 pm ET

Official Medicare GLP-1 Bridge program support

1‑800‑633‑4227

Covered medicines

Wegovy® pen

Available dose

NDC number

0.25 mg/0.5 mL

0169-4525-14 

0.5 mg/0.5 mL

0169-4505-14 

1 mg/0.5 mL

0169-4501-14 

1.7 mg/0.75 mL

0169-4517-14 

2.4 mg/0.75 mL

0169-4524-14 

Wegovy® HD pen

Available dose

NDC number

7.2 mg/0.75 mL

0169-4572-14

Wegovy® pill

Available dose

NDC number

1.5 mg

0169-4415-31

4 mg

0169-4404-31

9 mg

0169-4409-31

25 mg

0169-4425-31

FAQs

Frequently asked questions

Where do I submit the prior authorization?

CMS strongly encourages providers to submit prior authorization requests for the Medicare GLP-1 Bridge electronically through CoverMyMeds®. You can also submit via fax at 1-800-530-2404 using the official CMS Medicare GLP-1 Bridge Form.

Do I need to be enrolled as a Medicare provider to prescribe?

No. The Centers for Medicare and Medicaid Services (CMS) does not require providers to be enrolled in Medicare to prescribe Wegovy® to eligible Medicare patients under Medicare GLP-1 Bridge.

Which patients qualify for Medicare GLP-1 Bridge?

Medicare GLP-1 Bridge is for weight loss only. Adults aged 18 and older who have Medicare Part D and meet the following criteria at the time of initiating GLP-1 therapy may be eligible for the program:

BMI ≥ 35 (no additional medical conditions are required), or

BMI ≥ 30 with a diagnosis of one or more of the following:

  • heart failure with preserved ejection fraction
  • uncontrolled hypertension (defined as systolic blood pressure above 140 mm Hg or diastolic blood pressure above 90 mm Hg, despite concurrent treatment with two antihypertensive medications)
  • chronic kidney disease stage 3a or above; or

BMI ≥ 27 with a diagnosis of one or more of the following:

  • pre-diabetes (as defined by American Diabetes Association guidelines)
  • previous myocardial infarction
  • previous stroke
  • symptomatic peripheral artery disease
Does the Bridge program fall under Medicare Part D?

No. Medicare GLP-1 Bridge operates outside of the Medicare Part D benefit’s coverage and payment flow. As a result, Part D sponsors will not carry risk for eligible GLP-1 drugs furnished under the Medicare GLP-1 Bridge, and Part D sponsors do not have to opt in to the Medicare GLP-1 Bridge for eligible beneficiaries to access these drugs.

CMS will use a single central processor to manage prior authorization, claims adjudication, and payment to pharmacies for Medicare GLP-1 Bridge.

What happens to the program after December 31, 2027?

Medicare GLP-1 Bridge is a temporary demonstration program that expires December 31, 2027. Until then, CMS will gather data about the program’s usage. CMS has not yet announced whether the program will continue past 2027.

Does Novocare® fill prescriptions through Medicare GLP-1 Bridge?

Not at this time. Providers must fill prescriptions through the patient’s selected pharmacy.

Does my patient need a separate order for needles?

No, a separate prescription for needles is not needed since they are integrated into the Wegovy® pen device. 

If my patient switches from Wegovy® pen to Wegovy® pill or vice-versa, do I need to request a new prior authorization?

No, Medicare GLP-1 Bridge patients do not need a new prior authorization if switching between Wegovy® pen and pill.

Does Novocare® fill prescriptions through Medicare GLP-Bridge?

Not at this time. Providers must fill prescriptions through the patient's selected pharmacy.